CORRECTING and REPLACING MannKind Corporation Reports Third Quarter Financial Results

http://www.businesswire.com/news/home/20091102006260/en

- Conference Call Today at 5:00 p.m. EST -
VALENCIA, Calif.--(Business Wire)--
Eighth graph, last sentence of release should read: A telephone replay will be
accessible for approximately 14 days following completion of the call by dialing
(888) 393-9645 or (203) 369-3721 and entering conference number 7091682 (sted A
telephone replay will be accessible for approximately 14 days following
completion of the call by dialing (800) 393-9645 or (203) 369-3721 and entering
conference number 7091682.).

The corrected release reads:

MANNKIND CORPORATION REPORTS THIRD QUARTER FINANCIAL RESULTS

- Conference Call Today at 5:00 p.m. EST -

MannKind Corporation (Nasdaq:MNKD) today reported financial results for the
third quarter ended September 30, 2009.

For the third quarter of 2009, total operating expenses were $42.8 million,
compared to $69.1 million for the third quarter of 2008. Research and
development (R&D) expenses were $30.5 million for the third quarter of 2009
compared to $55.6 million for the same quarter in 2008, a decrease of $25.2
million. This 45% decrease was primarily due to reduced costs associated with
the clinical development of AFRESA as the Company completed its pivotal AFRESA
trials in 2008, as well as decreases in clinical supplies costs. General and
administrative (G&A) expenses decreased by $1.2 million or 9% to $12.3 million
for the third quarter of 2009 compared to $13.4 million in the third quarter of
2008.

For the first nine months of 2009, operating expenses totaled $154.0 million,
compared to $224.0 million in the first nine months of 2008. R&D expenses for
the first nine months were $113.2 million, compared to $181.7 million in 2008, a
decrease of $68.4 million. The 38% decrease in R&D expenses for the first nine
months was primarily due to decreased costs associated with the clinical
development of AFRESA as the Company completed its pivotal AFRESA trials in
2008, as well as decreases in cost of clinical supplies. G&A expenses decreased
by $1.6 million or 4% to $40.7 million for the first nine months of 2009 as
compared to $42.4 million in the same period in 2008. The decrease in G&A
expenses for the first nine months of 2009 was primarily due to the
nonrecurrence of costs associated with the purchase of patents during the first
quarter of 2008, which was partially offset in 2009 by increased professional
fees related to the insulin acquisition transaction with Pfizer Inc. during the
second quarter of 2009 and partnership discussions during the third quarter of
2009.

The net loss applicable to common stockholders for the third quarter of 2009 was
$45.6 million, or $0.42 per share, based on 108.8 million weighted average
shares outstanding. This compares to a net loss applicable to common
stockholders of $68.5 million, or $0.67 per share, based on 101.6 million
weighted average shares outstanding for the third quarter of 2008.

The net loss applicable to common stockholders for the first nine months of 2009
was $160.6 million, or $1.54 per share based on 104.4 million weighted average
shares outstanding, compared with a net loss applicable to common stockholders
of $219.7 million, or $2.17 per share based on 101.5 million weighted average
shares outstanding, for the first nine months of 2008.

Cash, cash equivalents and marketable securities were $56.6 million at September
30, 2009 and $46.5 million at December 31, 2008. Currently, the Company has
$200.0 million of available borrowings under the loan agreement with an entity
controlled by the Company`s principal stockholder.

"While we continue to be fully engaged in the task of navigating our NDA through
the FDA review process, we are continuing to run additional studies of AFRESA.
The results to date are preliminary, but we have nonetheless observed some
interesting and exciting findings," said Alfred Mann, Chairman and Chief
Executive Officer. "The more we study our product in different settings and
under different conditions, the more we can appreciate how it has the potential
to change the way diabetes is treated. In addition, as we get closer to our
January 2010 PFUFA date for the first generation of AFRESA, we are increasing
the pace of development of the next generation inhaler in order to provide soon
an even better therapeutic option for the millions of patients with diabetes."

Conference Call

MannKind management will host a conference call to discuss these results today
at 5:00 p.m. Eastern Time. To participate in the call please dial (888) 677-5721
or (210) 839-8507. To listen to the call via the Internet please visit
http://www.mannkindcorp.com. The web site replay will be available for 14 days.
A telephone replay will be accessible for approximately 14 days following
completion of the call by dialing (888) 393-9645 or (203) 369-3721 and entering
conference number 7091682.

Presenting from the Company will be:

* Chairman and Chief Executive Officer Alfred Mann
* President and Chief Operating Officer Hakan Edstrom
* Corporate Vice President and Chief Financial Officer Matthew Pfeffer
* Corporate Vice President and Chief Scientific Officer Peter Richardson

About MannKind Corporation

MannKind Corporation (Nasdaq:MNKD) focuses on the discovery, development and
commercialization of therapeutic products for patients with diseases such as
diabetes and cancer. Its pipeline includes AFRESA, MKC253, MKC1106-PP, and
MKC1106-MT. MannKind has submitted an NDA to the FDA requesting approval of
AFRESA for the treatment of adults with type 1 or type 2 diabetes for the
control of hyperglycemia. Its other programs are currently in Phase 1 clinical
trials. MannKind maintains a website at http://www.mannkindcorp.com to which
MannKind regularly posts copies of its press releases as well as additional
information about MannKind. Interested persons can subscribe on the MannKind
website to e-mail alerts that are sent automatically when MannKind issues press
releases, files its reports with the Securities and Exchange Commission or posts
certain other information to the website.

Forward-Looking Statements

This press release contains forward-looking statements, including statements
related to the potential of the Company`s products, including AFRESA, and the
results of clinical trials, that involve risks and uncertainties. Words such as
"believes," "anticipates," "plans," "expects," "intend," "will," "goal,"
"potential" and similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based upon the Company's
current expectations. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking statements as a result
of these risks and uncertainties, which include, without limitation, risks
inherent in the progress, timing and results of clinical trials, difficulties or
delays in seeking or obtaining regulatory approval, intellectual property
matters and other risks detailed in MannKind's filings with the Securities and
Exchange Commission, including the Annual Report on Form 10-K for the year ended
December 31, 2008 and periodic reports on Form 10-Q and Form 8-K. You are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. All forward-looking statements
are qualified in their entirety by this cautionary statement, and MannKind
undertakes no obligation to revise or update any forward-looking statements to
reflect events or circumstances after the date of this press release.

MannKind Corporation
(A Development Stage Company)
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except per share amounts)

Three months ended Nine months ended Cumulative period from

September 30,
September 30,
February 14, 1991

(date of inception)

to September 30,
2009 2008 2009 2008 2009
Revenue $ - $ - $ - $ 20 $ 2,988
Operating expenses:
Research and development 30,494 55,645 113,232 181,665 1,110,714
General and administrative 12,273 13,435 40,727 42,365 286,569
In-process research and development costs - - - - 19,726
Goodwill impairment - - - - 151,428
Total operating expenses 42,767 69,080 153,959 224,030 1,568,437
Loss from operations (42,767 ) (69,080 ) (153,959 ) (224,010 ) (1,565,449 )
Other income (expense) 149 (7 ) 503 (7 ) (1,440 )
Interest expense on note payable to principal stockholder (1,816 ) - (3,806 ) - (5,329 )
Interest expense on senior convertible notes (1,130 ) (124 ) (3,376 ) (585 ) (9,333 )
Interest income 9 715 67 4,858 36,928
Loss before provision for income taxes (45,555 ) (68,496 ) (160,571 ) (219,744 ) (1,544,623 )
Income taxes - - - - (26 )
Net loss (45,555 ) (68,496 ) (160,571 ) (219,744 ) (1,544,649 )
Deemed dividend related to beneficial conversion feature of convertible preferred stock - - - - (22,260 )
Accretion on redeemable preferred stock - - - - (952 )
Net loss applicable to common stockholders $ (45,555 ) $ (68,496 ) $ (160,571 ) $ (219,744 ) $ (1,567,861 )
Net loss per share applicable to common stockholders - basic and diluted $ (0.42 ) $ (0.67 ) $ (1.54 ) $ (2.17 )
Shares used to compute basic and diluted net loss per share applicable to common stockholders 108,779 101,647 104,402 101,495

MannKind Corporation
(A Development Stage Company)
Condensed Consolidated Balance Sheet
(Unaudited)
(in thousands)

September 30, 2009 December 31, 2008
Assets
Current assets:
Cash and cash equivalents $ 53,918 $ 27,648
Marketable securities 2,649 18,844
State research and development credit exchange receivable - current 1,500 1,500
Prepaid expenses and other current assets 5,247 5,983
Total current assets 63,314 53,975
Property and equipment - net 224,057 226,436
State research and development credit exchange receivable - net of current portion 700 1,500
Other assets 584 548
Total $ 288,655 $ 282,459

Liabilities and Stockholders` Equity (Deficit)

Current liabilities $ 28,425 $ 53,472
Senior convertible notes 112,635 112,253
Note payable to principal stockholder 150,000 30,000
Stockholders` equity (deficit) (2,405 ) 86,734
Total $ 288,655 $ 282,459

MannKind Corporation
Matthew Pfeffer
Chief Financial Officer
661-295-4784
mpfeffer@mannkindcorp.com

Copyright Business Wire 2009